Strategic Collaborations for Expanding Liquid Biopsy Use Globally​

  • Florian Klemm, MD, PhD – Technical Product Manager, SOPHiA GENETICS​

  • Ryan Demers, MSc – Global Diagnostics Director, Lung and Liquid Biopsy Strategy, AstraZeneca​

  • Persephone du Parcq, MSc, PGDip, - Deputy Operations Lead, Synnovis

MSK-ACCESS® powered with SOPHiA DDM™ offers an innovative and decentralized solution that combines MSK’s expertise in cancer genomics with the robust analytics of the SOPHiA DDM™ Platform. This application aims to address the global inequalities in comprehensive cancer care.​

Watch to hear about the collaborative efforts of SOPHiA GENETICS and AstraZeneca in expanding global access to and adoption of MSK-ACCESS® powered with SOPHiA DDM™. In this session, you will​

  • Learn about the decentralized approach, technology, and the analytical performance of this liquid biopsy application.​

  • Explore the journey of creating a global network for liquid biopsy testing, including efforts to reach underserved regions where access is limited.​

  • Gain insights from the first hands-on experience with MSK-ACCESS® powered with SOPHiA DDM™ from one of the early-access healthcare institutions.​

Register here for the event